| Disease | uveitis |
| Phenotype | C0553662|juvenile arthritis |
| Sentences | 1 |
| PubMedID- 24359625 | Infliximab and adalimumab can be considered as second-line immunomodulatory agents for the treatment of uveitis associated with juvenile arthritis. |
Page: 1